Roche is entering two fresh partnerships with drug discovery biotechs Atavistik Bio and Earendil Labs to develop new ...
Sarepta pays Regenxbio $39M to settle Elevidys patent suit; Viking prices $500M offering post-VK2735 data; BigHat raises $75M ...
Epic paused AI dev 6 weeks after rogue AI hacks; CEO Judy Faulkner cites cyberattacks. UCSF's Robert Wachter warns slowing ...
The biotech’s experimental drug remlifanserin failed to achieve its primary goal, but it saw enough signal to continue forward into Phase 3 — with a caveat.
FDA approves Elevar's Lyrfigtu as a second-line option for FGFR2-altered bile duct cancer, citing a 46% response rate in REFOCUS.
Uğur Şahin and Özlem Türeci are set to leave BioNTech by the end of the year and establish a new company dedicated to next-generation mRNA innovations. BioNTech itself will narrow ...
The FDA on Tuesday flagged more than 70 cases of severe liver injury and eight deaths associated with Amgen’s autoimmune treatment Tavneos, but the company said it previously ...
FDA advisers press Grail on false positives and missing mortality data for its Galleri multi-cancer test ahead of a Wednesday ...
A Shanghai and Boston biotech led by a veteran transpacific drug developer has secured more than $80 million to advance three clinical-stage brain-health drugs. NeuShen Therapeutics ...
Life sentence in China vaccine scandal; Flagship lands $47M defense contract; Caliway Dercum's win; BMS cuts 265 NJ jobs.
USTR hears testimony for and against tariffs on German-made drugs as nine European pharma chairs press EU governments on ...
FDA warns Empower Pharmacy for 3rd time over GLP-1 drugs tirzepatide & semaglutide, citing copies of brand-name treatments & ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results